中枢神经系统谷氨酸转运体的研究进展

在中枢神经系统,谷氨酸转运体在谷氨酸一谷氨酰胺循环中发挥着重要作用。谷氨酸转运体有高亲和力转运体,即兴奋性氨基酸转运体（excitatory amino acid transporters,EAATs）和低亲和力转运体,即囊泡谷氨酸转运体（vesicular glutamate transporters,VGLUTs）两种类型。其中,VGLUTs的功能是特异地将突触囊泡外的谷氨酸转运进入突触囊泡内,它包括三个成员,分别是VGLUT1、VGLUT2和VGLUT3。一方面,VGLUT1和VGLUT2标记了所有的谷氨酸能神经元,是谷氦酸能神经元和它们轴突末端高度特异的标志;另一方面,VGLUT1标志着皮质一皮质投射,而VGLUT2则标志着丘脑一皮层投射,VGLUT3则位于抑制性突触末端。     

囊泡膜谷氨酸转运体阳性纤维在大鼠三叉神经运动核内的分布

目的观察I、Ⅱ型囊泡膜谷氨酸转运体阳性纤维在大鼠三叉神经运动核内的分布。方法首先采用免疫荧光三重标记I、Ⅱ型囊泡膜谷氨酸转运体和神经元核蛋白以观察I、Ⅱ型囊泡膜谷氨酸转运体阳性纤维在大鼠三叉神经运动核内的分布;接着注射四甲基罗达明人下颌舌骨肌神经逆行标记三叉神经运动核开口神经元,再采用免疫荧光双重标记I型囊泡膜谷氨酸转运体和神经元核蛋白以观察I、Ⅱ型囊泡膜谷氨酸转运体阳性纤维在大鼠三叉神经运动核开口神经元区和闭口神经元区内的分布差异。结果I型囊泡膜谷氨酸转运体阳性纤维仅在三叉神经运动核背外侧部分布,而Ⅱ型囊泡膜谷氨酸转运体阳性纤维在整个三叉神经运动核内分布;开口神经元区未观察到I型囊泡膜谷氨酸转运体阳性终末。结论闭口神经元接受I、Ⅱ型囊泡膜谷氨酸转运体阳性纤维支配,开口神经元仅仅接受Ⅱ型囊泡膜谷氨酸转运体阳性纤维支配。     

高亲和力谷氨酸转运体结构和功能的研究进展

真核生物高亲和力谷氨酸转运体(excitatory amino acid transporters,EAATs)分为GLAST(EAAT1)、GLT-1(EAAT2)、EAAC1(EAAT3)、EAAT4和EAAT5等5个亚型.高亲和力谷氨酸转运体结构学的研究,揭示了谷氨酸转运体的跨膜拓扑结构、真核和原核生物EAATs结构的差异,以及在底物转运过程中的一些底物和协同转运离子的结合位点.其功能学的研究发现,EAATs在参与突触的传递,避免兴奋性氨基酸的毒性效应中发挥重要作用,同时也参与了对学习、记忆以及运动行为的调控.结合我们既往的工作,就近几年EAATs的结构和功能研究做一综述.     

GABA在中枢神经系统发育的早期阶段具有兴奋作用

在发育早期中枢神经系统γ－氨基丁酸（γ-aminobutyric acid,GABA）主要作为兴奋性神经递质而发挥作用,它可使神经元产生去极化,升高胞内Ca^2 浓度,此时GABA发挥了重要的神经营养性作用,随着兴奋性谷氨酸能系统的发育,通过Cl^-转运体的表达变化,胞内Cl^-浓度降低,从而使GABA由兴奋性转变为抑制性。     

岗田酸诱导大鼠脑神经细胞表达谷氨酸转运体EAAT1

为研究tau蛋白高度磷酸化与谷氨酸转运体功能之间的关系,实验采用免疫组织化学、荧光双标记技术及大鼠额叶皮质定位注射的方法,观察了蛋白磷酸酶抑制剂岗田酸（okadaic acid,OA)所致神经细胞退化对谷氨酸转运体亚型EAAT1表达的影响。结果如下：（1）在OA注射中心区神经元早期出现胞体固缩、肿胀、核移位,在注射3d时细胞破碎,发生坏死,并有大量炎性细胞浸润等病理现象;边周区细胞呈AT8（微管相关蛋白tau磷酸化指标）免疫阳性反应;（2）OA首先诱导神经细胞突起远端tau蛋白磷酸化,并逐渐向胞体发展,形成营养不良的神经细胞突起和神经纤维缠结样病理改变;（3）AT8免疫阳性反应脑区的神经细胞高表达谷氨酸转运体EAAT1,在12h阳性表达细胞数显著增多（P＜0．01）,1d时达峰值（P＜0．001）,3d时明显减少。在OA作用下EAAT1表达于星形胶质细胞和神经元。结果提示,OA致微管相关蛋白tau高度磷酸化时可诱导该区星形胶质细胞和神经元高表达谷氨酸转体EAAT1。EAAT1高表达的病理生理意义有待进一步的阐明。     

谷氨酸促进大鼠海马神经元的内钙升高

谷氨酸能影响大鼠海马神经元胞内钙信号的变化,进而影响海马神经元神经冲动的发放和学习记忆过程。运用荧光测钙技术实时监测了大鼠海马神经元内钙信号的动态变化,同时分析了谷氨酸对其胞内钙信号的影响。试验表明：谷氨酸能够显著提高胞内游离钙离子的浓度;细胞外钙离子的存在、谷氨酸刺激时间及刺激频率的增加都能引起胞内钙信号不同程度的升高;但谷氨酸的过度刺激会引起钙离子浓度的超负荷,从而导致神经元结构和功能的损坏。     

谷氨酸转运体能引发突触前离子流

谷氨酸转运体的功能是在递质出胞释放后清除突触间隙的递质 ,但转运体也携带离子。已证实在突触后膜和胶质细胞 ,转运体的激活可导致离子流的产生。某些谷氨酸转运体也存在于突触前终末 ,它们的活动可能影响突触前膜的电位 ,从而调节递质释放。但是 ,突触前终末的体积极小 ,在这些部位记录转运体介导的电流是一件较难的事情。最近 ,Palmer等通过记录两种大型的突触前终末 ,证实了谷氨酸转运体的确能引发突触前离子流。研究者记录了金鱼视网膜双极细胞的大型终末 ,发现突触前离子流与谷氨酸的释放相伴发生 ,这一离子流有较大的电导系数 ,且…     

胆碱转运体与阿尔茨海默病

阿尔茨海默病主要病理学特征是在脑中形成大量的老年斑和神经元纤维缠结以及出现弥漫性脑萎缩.胆碱能系统的失调与阿尔茨海默病的发生机制关系密切.具体表现为基底前脑的胆碱能系统紊乱,胆碱乙酰化酶、乙酰胆碱含量显著减少,以及大量胆碱能神经元退化.胆碱转运体是胆碱能系统中用于转运胆碱进入细胞的关键蛋白体,有三种类型:高亲和力胆碱转运体、胆碱转运体类蛋白及非特异性有机阳离子转运体.近年,很多研究表明胆碱转运体的异常与一系列神经退行性紊乱有关.本文简要综述胆碱能系统中胆碱转运体的生理作用及其在阿尔茨海默病中异常代谢和可能机制的研究进展,以期为防治阿尔茨海默病提供进一步的理论和实验依据.     

激光共聚焦扫描显微镜和透射电镜观察大鼠纹状体内谷氨酸能突触连接的对比观察

目的 探讨使用激光共聚焦扫描显微镜 (Laser scanning confocal microscope,LSCM)观察大鼠纹状体内谷氨酸能突触连接的方法的可行性.方法 12只正常大鼠分为两组,6只大鼠进行纹状体中等棘刺神经元的CM-DiI 单细胞标记,然后Ⅰ型囊泡膜谷氨酸转运体(vesicular glutamate transporter 1,VGluT1 )免疫荧光标记,LSCM层扫后三维重建,观察VGluT1阳性位点在中等棘刺神经元树突上的分布.另外6只大鼠用TEM观察不对称性突触在纹状体神经元树突上的分布.对两种方法的结果进行比较.结果 用LSCM 和TEM方法观察到的纹状体神经元上谷氨酸能突触连接分布情况一致,没有统计学差异.但LSCM更具优越性的是,可以对图像进行三维重构,从而有利于对神经元之间突触连接的空间分布观察和定量分析.结论 神经细胞荧光标记技术结合LSCM观察是考察纹状体神经元上谷氨酸能突触连接的有效方法.     

高糖环境对Mu ller细胞谷氨酸转运体及谷氨酰胺合成酶表达的影响

目的：研究高糖环境对原代培养新生7天SD乳鼠视网膜Muller细胞谷氨酸转运合成系统的影响及其可能机制。方法：新生7天SD乳鼠视网膜Muller细胞原代培养并模拟高糖环境构建乳鼠视网膜muller细胞体外高糖环境模型。处理分为3组：对照组,高糖组,高糖＋白藜芦醇干预组。培养时间为24h,通过westernblot等检测方法,对照观察各组Muller细胞谷氨酸转运体（GLAST）、谷氨酰胺合成酶（GS）的表达情况。结果：模拟高糖环境可以造成新生SD乳鼠视网膜Muller细胞谷氨酸转运体（GLAST）表达的降低（0．225foldVScontrol,P〈0．05）,并导致其表达的谷氨酰胺合成酶（GS）表达水平的显著降低（0．653foldVScontrol,P〈0．05）;而干预药物白藜芦醇作用后可明显逆转新生SD乳鼠Mu ller细胞谷氨酸转运体（GLAST）（1．133foldvSHGgroup,P〈0．05）、谷氨酰胺合成酶（GS）（1．720foldVSHGgroup,P〈0．05）等蛋白的表达水平。结论：模拟高糖环境可以影响视网膜M0ller细胞谷氨酸转运体（GLAST）、谷氨酰胺合成酶的表达,其结局可能导致视神经细胞因谷氨酸堆积而导致的兴奋性毒性,白藜芦醇能提高Mcjller细胞谷氨酸转运体（GLAST）、谷氨酰胺合成酶表达,从而保护视神经细胞。     

Glutamate forward and reverse transport: from molecular mechanism to transporter-mediated release after ischemia

Glutamate transporters remove the excitatory neurotransmitter glutamate from the extracellular space after neurotransmission is complete, by taking glutamate up into neurons and glia cells. As thermodynamic machines, these transporters can also run in reverse, releasing glutamate into the extracellular space. Because glutamate is excitotoxic, this transporter-mediated release is detrimental to the health of neurons and axons, and it, thus, contributes to the brain damage that typically follows a stroke. This review highlights current ideas about the molecular mechanisms underlying glutamate uptake and glutamate reverse transport. It also discusses the implications of transporter-mediated glutamate release for cellular function under physiological and patho-physiological conditions.     

谷氨酸转运体与疼痛

中枢神经系统谷氨酸生理浓度主要依赖神经细胞和神经胶质细胞上谷氨酸转运体维持,谷氨酸转运体的功能紊乱会导致谷氨酸的累积。谷氨酸转运体在吗啡镇痛及耐受中扮演一定的角色,并在神经病理性痛中发挥重要作用。谷氨酸转运体可能作为治疗疼痛的一个潜在的药物靶点。     

Distribution of extracellular glutamate in the neuropil of hippocampus

Reported values of extracellular glutamate concentrations in the resting state depend on the method of measurement and vary ～1000-fold. As glutamate levels in the micromolar range can cause receptor desensitization and excitotoxicity, and thus affect neuronal excitability, an accurate determination of ambient glutamate is important. Part of the variability of previous measurements may have resulted from the sampling of glutamate in different extracellular compartments, e.g., synaptic versus extrasynaptic volumes. A steep concentration gradient of glutamate between these two compartments could be maintained, for example, by high densities of glutamate transporters arrayed at the edges of synapses. We have used two photon laser scanning microscopy and electrophysiology to investigate whether extracellular glutamate is compartmentalized in acute hippocampal slices. Pharmacological blockade of NMDARs had no effect on Ca(2+) transients generated in dendritic shafts or spines of CA1 pyramidal neurons by depolarization, suggesting that ambient glutamate is too low to activate a significant number of NMDARs. Furthermore, blockade of transporters did not flood the synapse with glutamate, indicating that synaptic NMDARs are not protected from high concentrations of extrasynaptic glutamate. We suggest that, in the CA1 region of hippocampus, glutamate transporters do not create a privileged space within the synapse but rather keep ambient glutamate at very low levels throughout the neuropil.     

Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal.

Na(+)-dependent transporters for glutamate exist on astrocytes (EAAT1 and EAAT2) and neurons (EAAT3). These transporters presumably assist in keeping the glutamate concentration low in the extracellular fluid of brain. Recently, Na(+)-dependent glutamate transport was described on the abluminal membrane of the blood-brain barrier. To determine whether the above-mentioned transporters participate in glutamate transport of the blood-brain barrier, total RNA was extracted from bovine cerebral capillaries. cDNA for EAAT1, EAAT2, and EAAT3 was observed, indicating that mRNA was present. Western blot analysis demonstrated all three transporters were expressed on abluminal membranes, but none was detectable on luminal membranes of the blood-brain barrier. Measurement of transport kinetics demonstrated voltage dependence, K(+)-dependence, and an apparent K(m) of 14 microM (aggregate of the three transporters) at a transmembrane potential of -61 mV. Inhibition of glutamate transport was observed using inhibitors specific for EAAT2 (kainic acid and dihydrokainic acid) and EAAT3 (cysteine). The relative activity of the three transporters was found to be approximately 1:3:6 for EAAT1, EAAT2, and EAAT3, respectively. These transporters may assist in maintaining low glutamate concentrations in the extracellular fluid.     

Modulation of synaptic transmission by astrocytes in the rat supraoptic nucleus.

One of the functions of astroglial cells in the central nervous system is to clear synaptically-released glutamate from the extracellular space. This is performed thanks to specific transporters of the excitatory amino acid expressed on their surface. The way by which astrocytic glutamate uptake contributes to synaptic transmission has been investigated via numerous experimental approaches but has never been addressed under conditions where neuroglial interactions are physiologically modified. Recently, we took advantage of the neuroglial plastic properties of the hypothalamo-neurohypophysial system to examine the consequences of a physiological reduction in the astrocytic coverage of neurons on glutamatergic synaptic transmission. This experimental model has brought some insights on the physiological interactions between glial cells and neurons at the level of the synapse. In particular, it has revealed that the degree of glial coverage of neurons influences glutamate concentration at the vicinity of excitatory synapses and, as a consequence, affects the level of activation of presynaptic glutamate receptors. Astrocytes, therefore, appear to contribute to the regulation of neuronal excitability by modulating synaptic efficacy at glutamatergic nerve terminals.     

Glial glutamate transporters: New actors in brain signaling

Glutamate, the main excitatory amino acid in the vertebrate brain, is critically involved in most of the physiological functions of the central nervous system. It has traditionally been assumed that glutamate triggers a wide array of signaling cascades through the activation of specific membrane receptors. The extracellular levels are tightly regulated to prevent neurotoxic insults. Electrogenic Na(+)-dependent glial glutamate transporters remove the bulk of the neurotransmitter from the synaptic cleft. An exquisitely ordered coupling between glutamatergic neurons and surrounding glia cells is fundamental for excitatory transmission. The glutamate/glutamine and astrocyte/neuron lactate shuttles provide the biochemical framework of this compulsory association. In this context, recent advances show that glial glutamate transporters act as signal transducers that regulate the expression of proteins involved in their compartmentalization with neurons in the so-called tripartite synapse.     

Microglial self-defence mediated through GLT-1 and glutathione

Glutamate is stored in synaptic vesicles in presynaptic neurons. It is released into the synaptic cleft to provide signalling to postsynaptic neurons. Normally, the astroglial glutamate transporters GLT-1 and GLAST take up glutamate to mediate a high signal-to-noise ratio in the synaptic signalling, and also to prevent excitotoxic effects by glutamate. In astrocytes, glutamate is transformed into glutamine, which is safely transported back to neurons. However, in pathological conditions, such as an ischemia or virus infection, astroglial transporters are down-regulated which could lead to excitotoxicity. Lately, it was shown that even microglia can express glutamate transporters during pathological events. Microglia have two systems for glutamate transport: GLT-1 for transport into the cells and the x_c⁻ system for transport out of the cells. We here review results from our work and others, which demonstrate that microglia in culture express GLT-1, but not GLAST, and transport glutamate from the extracellular space. We also show that TNF-α can induce increased microglial GLT-1 expression, possibly associating the expression with inflammatory systems. Furthermore, glutamate taken up through GLT-1 may be used for direct incorporation into glutathione and to fuel the intracellular glutamate pool to allow cystine uptake through the x_c⁻ system. This can lead to a defence against oxidative stress and have an antiviral function.     

Electrogenic Glutamate Transporters in the CNS: Molecular Mechanism,Pre-steady-state Kinetics,and their Impact on Synaptic Signaling

Glutamate is the major excitatory neurotransmitter in the mammalian CNS. The spatiotemporal profile of the glutamate concentration in the synapse is critical for excitatory synaptic signalling. The control of this spatiotemporal concentration profile requires the presence of large numbers of synaptically localized glutamate transporters that remove pre-synaptically released glutamate by uptake into neurons and adjacent glia cells. These glutamate transporters are electrogenic and utilize energy stored in the transmembrane potential and the Na⁺/K⁺-ion concentration gradients to accumulate glutamate in the cell. This review focuses on the kinetic and electrogenic properties of glutamate transporters, as well as on the molecular mechanism of transport. Recent results are discussed that demonstrate the multistep nature of the transporter reaction cycle. Results from pre-steady-state kinetic experiments suggest that at least four of the individual transporter reaction steps are electrogenic, including reactions associated with the glutamate-dependent transporter halfcycle. Furthermore, the kinetic similarities and differences between some of the glutamate transporter subtypes and splice variants are discussed. A molecular mechanism of glutamate transport is presented that accounts for most of the available kinetic data. Finally, we discuss how synaptic glutamate transporters impact on glutamate receptor activity and how transporters may shape excitatory synaptic transmission.     

Glutamate Transporters: Expression and Function in Oligodendrocytes

Glutamate, the main excitatory neurotransmitter of the vertebrate central nervous system (CNS), is well known as a regulator of neuronal plasticity and neurodevelopment. Such glutamate function is thought to be mediated primarily by signaling through glutamate receptors. Thus, it requires a tight regulation of extracellular glutamate levels and a fine-tuned homeostasis that, when dysregulated, has been associated with a wide range of central pathologies including neuropsychiatric, neurodevelopmental, and neurodegenerative disorders. In the mammalian CNS, extracellular glutamate levels are controlled by a family of sodium-dependent glutamate transporters belonging to the solute carrier family 1 (SLC1) that are also referred to as excitatory amino acid transporters (EAATs). The presumed main function of EAATs has been best described in the context of synaptic transmission where EAATs expressed by astrocytes and neurons effectively regulate extracellular glutamate levels so that synapses can function independently. There is, however, increasing evidence that EAATs are expressed by cells other than astrocytes and neurons, and that they exhibit functions beyond glutamate clearance. In this review, we will focus on the expression and functions of EAATs in the myelinating cells of the CNS, oligodendrocytes. More specifically, we will discuss potential roles of oligodendrocyte-expressed EAATs in contributing to extracellular glutamate homeostasis, and in regulating oligodendrocyte maturation and CNS myelination by exerting signaling functions that have traditionally been associated with glutamate receptors. In addition, we will provide some examples for how dysregulation of oligodendrocyte-expressed EAATs may be involved in the pathophysiology of neurologic diseases.

     

Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity

Huntington disease (HD) is characterized by the preferential loss of striatal medium-sized spiny neurons (MSNs) in the brain. Because MSNs receive abundant glutamatergic input, their vulnerability to excitotoxicity may be largely influenced by the capacity of glial cells to remove extracellular glutamate. However, little is known about the role of glia in HD neuropathology. Here, we report that mutant huntingtin accumulates in glial nuclei in HD brains and decreases the expression of glutamate transporters. As a result, mutant huntingtin (htt) reduces glutamate uptake in cultured astrocytes and HD mouse brains. In a neuron-glia coculture system, wild-type glial cells protected neurons against mutant htt-mediated neurotoxicity, whereas glial cells expressing mutant htt increased neuronal vulnerability. Mutant htt in cultured astrocytes decreased their protection of neurons against glutamate excitotoxicity. These findings suggest that decreased glutamate uptake caused by glial mutant htt may critically contribute to neuronal excitotoxicity in HD.